Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH35324 in Patients with Various Allergic Diseases
NCT05960708Phase 1Completed
- Sponsor
- Yuhan
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of YH35324 in chronic spontaneous urticaria (CSU) and Cold urticaria (CU) (7 arms), sponsored by Yuhan. Primary endpoint: Adverse Events at 57 days. Started Aug 2023; status: completed.
02
Drugs
YH35324
03
Conditions
chronic spontaneous urticaria (CSU)Cold urticaria (CU)
Beyond the preview
Go deeper on NCT05960708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960708.